1stOncology™: Cancer Intelligence Service – Page 64 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results

On August 3, 2026 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) reported financial results for the second quarter of 2026 (2Q26) and raised revenue guidance for 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

"Our second quarter results highlight strong execution and momentum across the business, delivering 16% year-over-year total revenue growth and driving a considerable increase to our full-year revenue guidance," said Renee Gala, president and chief executive officer of Jazz Pharmaceuticals. "We remain focused on long-term growth as we prepare to launch Ziihera in HER2+ 1L GEA, advance the zanidatamab and Epidiolex clinical programs, and expand our pipeline through targeted corporate development and internal research and development. The combination of commercial execution, portfolio expansion and our strong financial foundation positions Jazz to deliver meaningful innovation for patients and substantial value for shareholders."

Recent Key Highlights

•Highest ever total quarterly revenues of $1.2 billion with 16% year-over-year (YoY) growth.
•Generated GAAP / non-GAAP1 adjusted earnings per share (EPS) of $2.78 / $5.71 with $824 million in cash from operations in the first half of 2026.
•U.S. Food and Drug Administration (FDA) granted Priority Review and set Prescription Drug User Fee Act (PDUFA) target action date of August 25, 2026 for supplemental Biologics License Application (sBLA) for zanidatamab containing combinations in first-line (1L) gastroesophageal adenocarcinoma (GEA).
•Results from Phase 3 HERIZON-GEA-01 published in The New England Journal of Medicine; additional subgroup analyses presented in an oral presentation at the 2026 ASCO (Free ASCO Whitepaper) Annual Meeting showing improved clinical outcomes with zanidatamab-containing combinations regardless of PD-L1 expression, including in PD-L1-negative patients.
•FDA granted Breakthrough Therapy designation (BTD) for zanidatamab in adults with previously treated locally advanced, unresectable, or metastatic HER2-positive colorectal cancer (CRC).
•Following strong 1H26 commercial execution, the company raised its 2026 revenue guidance range to $4.60 – $4.75 billion, reflecting anticipated double-digit YoY revenue growth from both Xywav and the combined epilepsy and oncology franchises.

Business Updates

Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution:
•Xywav net product sales increased 13% YoY to $471 million in 2Q26.
•Robust new patient growth, with approximately 525 net patient adds in 2Q26. There were approximately 17,125 active patients exiting the quarter, comprised of approximately 11,275 narcolepsy patients and approximately 5,850 idiopathic hypersomnia (IH) patients.
•Continued physician and patient demand for the differentiated benefits of low-sodium Xywav.

Epidiolex/Epidyolex (cannabidiol):
•Epidiolex/Epidyolex net product sales increased 16% YoY to $292 million in 2Q26, driven by continued strong demand.
•Expanded Epidiolex development program to reach more patients with the following clinical trials: Phase 3 trial in developmental and epileptic encephalopathy (DEE), Phase 2/3 trial in juvenile myoclonic epilepsy (JME) and Phase 3b/4 trial in adult Lennox-Gastaut syndrome (LGS).
•Submitted New Drug Application (NDA) for cannabidiol capsule formulation to broaden utilization of cannabidiol in currently approved indications and increase flexibility for patients.

Ziihera (zanidatamab-hrii):
•Ziihera net product sales in biliary tract cancer (BTC) were $15 million in 2Q26.
•Prepared to launch zanidatamab in HER2+ 1L GEA (PDUFA date of August 25, 2026).
•Top-line results from the second interim overall survival (OS) analysis for the HERIZON-GEA-01 trial doublet regimen are expected in 3Q26.

Modeyso (dordaviprone):
•Modeyso net product sales were $48 million in 2Q26 with more than 600 patients having received Modeyso from product launch in August 2025 through the end of the second quarter of 2026.
•Anticipate the OS interim analysis for the event-driven Phase 3 ACTION trial in 1H27, based on current pace of event accrual.

Zepzelca (lurbinectedin):
•Zepzelca net product sales increased 42% YoY to $106 million in 2Q26, driven by continued uptake of the Zepzelca and atezolizumab combination in the 1L maintenance ES-SCLC setting, partially offset by a decline in second-line use.
•Based on the results from the LAGOON trial of Zepzelca in second-line metastatic SCLC, and in alignment with FDA, in 3Q26, we will submit for FDA’s review and subsequent action a labeling supplement to remove the second-line indication. The first-line maintenance indication will not be affected.

Corporate Development:
•Announced a preclinical research collaboration with AbCellera Biologics Inc. (AbCellera), to develop next-generation T-cell engaging multispecific antibodies for multiple gastrointestinal (GI) cancers and other solid tumors.
•The company continues to actively evaluate additional value-enhancing corporate development.

Financial Highlights
Three Months Ended
June 30, Six Months Ended
June 30,
(In millions, except per share amounts) 2026 2025 2026 2025
Total revenues $ 1,208.3 $ 1,045.7 $ 2,277.2 $ 1,943.5
GAAP net income (loss) $ 192.8 $ (718.5) $ 485.9 $ (811.0)
Non-GAAP adjusted net income (loss) $ 396.4 $ (504.8) $ 815.9 $ (399.6)
GAAP earnings (loss) per share $ 2.78 $ (11.74) $ 7.17 $ (13.28)
Non-GAAP adjusted earnings (loss) per share $ 5.71 $ (8.25) $ 12.04 $ (6.54)

GAAP and non-GAAP adjusted net income in 2Q26 includes acquired in-process research and development (IPR&D) expense of $77.0 million, relating to upfront payments made in connection with our collaboration and license agreement with AbCellera and asset purchase agreement to acquire remaining rights for JZP898 from Werewolf Therapeutics, Inc. (Werewolf). This impacted our GAAP and non-GAAP adjusted results by $65.4 million (net of tax of $11.6 million) or $0.94 per share.
GAAP and non-GAAP adjusted net loss in 2Q25 includes acquired IPR&D expense of $905.4 million representing the value allocated to Modeyso in the Chimerix Acquisition, which impacted our results by $14.78 per share and $14.75 per share on a GAAP and non-GAAP adjusted basis, respectively.
Reconciliations of applicable GAAP reported to non-GAAP adjusted information are included at the end of this press release.
Total Revenues
Three Months Ended
June 30, Six Months Ended
June 30,
(In millions) 2026 2025 2026 2025
Xywav $ 471.2 $ 415.3 $ 879.4 $ 760.1
Xyrem 30.5 35.4 61.7 72.6
Sleep 501.7 450.7 941.1 832.7
Epidiolex/Epidyolex 292.1 251.7 541.9 469.4
Epilepsy 292.1 251.7 541.9 469.4
Zepzelca 105.8 74.5 206.8 137.5
Rylaze/Enrylaze 99.5 100.7 203.2 194.9
Defitelio/defibrotide 62.0 48.1 109.4 88.8
Modeyso 48.2 0.5 89.6 0.5
Vyxeos 31.4 44.9 58.0 74.4
Ziihera 15.4 6.0 28.7 8.0
Oncology 362.3 274.7 695.7 504.1
Other — 8.5 2.7 18.8
Product sales, net 1,156.1 985.6 2,181.4 1,825.0
High-sodium oxybate AG royalty revenue 42.2 54.1 78.5 103.0
Other royalty and contract revenues 10.0 6.0 17.3 15.5
Total revenues $ 1,208.3 $ 1,045.7 $ 2,277.2 $ 1,943.5

Total revenues increased 16% in 2Q26 YoY primarily due to higher Xywav, Epidiolex/Epidyolex and Zepzelca net product sales and the inclusion of Modeyso net product sales, following FDA approval in August 2025.

Operating Expenses and Income Tax Expense (Benefit)
Three Months Ended
June 30, Six Months Ended
June 30,
(In millions, except percentages) 2026 2025 2026 2025
GAAP:
Cost of product sales $ 116.4 $ 116.3 $ 250.5 $ 220.9
Gross margin on total revenues 90.4% 88.9% 89.0% 88.6%
Selling, general and administrative $ 389.2 $ 358.4 $ 741.9 $ 872.4
% of total revenues 32.2% 34.3% 32.6% 44.9%
Research and development $ 207.5 $ 189.9 $ 403.5 $ 370.6
% of total revenues 17.2% 18.2% 17.7% 19.1%
Acquired in-process research and development $ 77.0 $ 905.4 $ 77.0 $ 905.4
Gain on sale of priority review voucher $ — $ — $ (122.8) $ —
Income tax expense (benefit) $ 18.1 $ (17.2) $ 24.2 $ (35.0)
Effective tax rate 8.6% 2.3% 4.7% 4.1%

Three Months Ended
June 30, Six Months Ended
June 30,
(In millions, except percentages) 2026 2025 2026 2025
Non-GAAP adjusted:
Cost of product sales $ 95.1 $ 76.3 $ 185.1 $ 146.0
Gross margin on total revenues 92.1% 92.7% 91.9% 92.5%
Selling, general and administrative $ 343.2 $ 310.3 $ 651.7 $ 782.6
% of total revenues 28.4% 29.7% 28.6% 40.3%
Research and development $ 184.9 $ 167.0 $ 357.2 $ 326.7
% of total revenues 15.3% 16.0% 15.7% 16.8%
Acquired in-process research and development $ 77.0 $ 905.4 $ 77.0 $ 905.4
Income tax expense $ 74.4 $ 42.2 $ 115.6 $ 78.7
Effective tax rate 15.8% (9.1)% 12.4% (24.6)%

Changes in operating expenses and income tax expense (benefit) in 2Q26 over the prior year period are primarily due to the following:
•Cost of product sales, on a GAAP and non-GAAP adjusted basis, increased in 2Q26, primarily due to higher royalty expenses, driven by higher revenues of Modeyso and Zepzelca, offset on a GAAP basis, by lower acquisition accounting inventory fair value step up expense.
•Selling, general and administrative (SG&A) expenses, on a GAAP and non-GAAP adjusted basis, increased in 2Q26, primarily due to higher marketing investment and compensation-related expenses in support of our commercial portfolio.
•Research and development (R&D) expenses, on a GAAP and non-GAAP adjusted basis, increased in 2Q26, driven by higher clinical studies costs, primarily related to zanidatamab.
•Acquired IPR&D, on a GAAP and non-GAAP adjusted basis, in 2Q26 comprised the upfront payments to AbCellera and Werewolf.
•Income tax expense, on a GAAP and non-GAAP adjusted basis, in 2Q26 reflects changes in the geographic mix of income and expenses compared to 2Q25.

(Press release, Jazz Pharmaceuticals, AUG 3, 2026, View Source [SID1234669609])

Handa Oncology Receives FDA Tentative Approval for OMCAZIO (cabozantinib) Capsules

On August 3, 2026 Handa Pharmaceuticals, Inc. ("Handa") (TSE:6620) reported that the U.S. Food and Drug Administration ("FDA") has granted tentative approval to OMCAZIO (cabozantinib) capsules, a novel alternate-salt formulation of cabozantinib developed by Handa’s U.S. subsidiary, Handa Oncology, LLC (the "Company").

OMCAZIO (cabozantinib) capsules are indicated for the treatment of:

adult patients with advanced renal cell carcinoma (RCC);
adult patients with advanced RCC, in combination with nivolumab, as a first-line treatment;
adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib;
adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic neuroendocrine tumors (epNET).
OMCAZIO was developed under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act. In bioavailability / bioequivalence studies, OMCAZIO was shown to be bioequivalent to CABOMETYX[1] at a lower dose, and demonstrated no clinically significant food effect, and improved absorption of cabozantinib.

Because OMCAZIO is bioequivalent to CABOMETYX at a lower dose, the OMCAZIO label includes the following recommendations for converting patients between the two products:

CABOMETYX tablets dosage OMCAZIO capsules dosage
60 mg once daily 34.5 mg once daily
40 mg once daily 23 mg once daily
20 mg once daily 11.5 mg once daily
"Tentative approval marks an important regulatory milestone for Handa. We developed OMCAZIO with the goal of providing an alternative oral cabozantinib formulation that may offer greater flexibility for patients and healthcare providers," said Bill Liu, Chairman and CEO of Handa. "We are continuing our commercial readiness activities and look forward to making OMCAZIO available to patients following FDA final approval."

A tentative approval indicates that FDA has determined that an application meets the agency’s standards for safety, effectiveness and manufacturing quality.

Cabozantinib is one of the commonly used oral targeted therapies in oncology. According to Exelixis, Inc., U.S. net product revenues for CABOMETYX were approximately $2.11 billion in 2025.[2]

IMPORTANT SAFETY INFORMATION

BOXED WARNING: RISK OF SERIOUS ADVERSE REACTIONS OR REDUCED EFFECTIVENESS DUE TO MEDICATION ERRORS
OMCAZIO is not substitutable on a mg-to-mg basis with other cabozantinib products. Inappropriate substitution or incorrect conversion of OMCAZIO capsules for another cabozantinib product can increase the risk of serious adverse reactions. Confirm that the intended cabozantinib product at the intended dosage and strength is being prescribed and dispensed.

WARNINGS AND PRECAUTIONS

Risk of Serious Adverse Reactions or Reduced Effectiveness Due to Medication Errors: Cabozantinib is available in multiple dosage forms and strengths. OMCAZIO is not substitutable on a mg-to-mg basis with other cabozantinib products. Confirm that the intended cabozantinib product is being prescribed and dispensed.
Hemorrhage: Do not administer OMCAZIO if recent history of hemorrhage.
Perforations and Fistulas: Monitor for symptoms. Discontinue OMCAZIO for Grade 4 events.
Thromboembolic Events: Discontinue OMCAZIO for myocardial infarction or serious venous or arterial thromboembolic events.
Hypertension and Hypertensive Crisis: Monitor blood pressure regularly. Interrupt OMCAZIO for hypertension not adequately controlled with anti-hypertensive therapy. Discontinue OMCAZIO for hypertensive crisis or severe hypertension that cannot be controlled.
Cardiac Failure: Monitor for signs and symptoms of cardiac failure throughout treatment.
Diarrhea: May be severe. Interrupt OMCAZIO until diarrhea resolves or improve to ≤Grade 1, then resume at reduced dose. Recommend standard antidiarrheal treatments.
Palmar-Plantar Erythrodysesthesia (PPE): Interrupt OMCAZIO treatment until PPE resolves or improves to Grade 1.
Hepatotoxicity: When used with nivolumab, higher frequencies of Grade 3 and 4 ALT and AST elevation may occur than with OMCAZIO alone. Monitor liver enzymes before initiation of and periodically throughout treatment. Consider withholding OMCAZIO and/or nivolumab, initiating corticosteroid therapy, and/or permanently discontinuing the combination for severe or life-threatening hepatotoxicity.
Adrenal Insufficiency: When used in combination with nivolumab, primary or secondary adrenal insufficiency may occur. For Grade 2 or higher adrenal insufficiency, initiate symptomatic treatment, including hormone replacement as clinically indicated. Withhold OMCAZIO and/or nivolumab depending on severity.
Proteinuria: Monitor urine protein. Interrupt OMCAZIO until proteinuria resolves to ≤Grade 1, resume OMCAZIO at a reduced dose. Discontinue for nephrotic syndrome.
Osteonecrosis of the jaw (ONJ): Withhold OMCAZIO for at least 3 weeks prior to invasive dental procedures and for development of ONJ.
Impaired Wound Healing: Withhold OMCAZIO for at least 3 weeks before elective surgery. Do not administer for at least 2 weeks following major surgery and adequate wound healing. The safety of resumption of OMCAZIO after resolution of wound healing complications has not been established.
Reversible Posterior Leukoencephalopathy Syndrome (RPLS): Discontinue OMCAZIO.
Thyroid Dysfunction: Monitor thyroid function before and during treatment with OMCAZIO.
Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception.
ADVERSE REACTIONS

The most common adverse reactions (≥20%) include:

OMCAZIO as a single agent: diarrhea, fatigue, palmar plantar erythrodysesthesia (PPE), decreased appetite, hypertension, nausea, vomiting, decreased weight, and constipation.
OMCAZIO in combination with nivolumab: diarrhea, fatigue, hepatotoxicity, PPE, stomatitis, rash, hypertension, hypothyroidism, musculoskeletal pain, decreased appetite, nausea, dysgeusia, abdominal pain, cough, and upper respiratory tract infection.
DRUG INTERACTIONS

Strong CYP3A inhibitors: Reduce the OMCAZIO dosage if coadministration cannot be avoided.
Strong or moderate CYP3A inducers: Increase the OMCAZIO dosage if coadministration cannot be avoided.
CONTRAINDICATION

None.

USE IN SPECIFIC POPULATIONS

Lactation: Advise not to breastfeed.
Pediatric Use: Monitor open growth plates in adolescent patients. Consider interrupting or discontinuing OMCAZIO if abnormalities occur.
About OMCAZIO

OMCAZIO is a novel alternate-salt capsule formulation of cabozantinib, a tyrosine kinase inhibitor. The formulation is engineered to improve absorption and can be administered with or without food. OMCAZIO has received tentative approval from the FDA and is not yet available for commercial distribution in the United States.

(Press release, Handa Oncology, AUG 3, 2026, View Source [SID1234669607])

Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies

On August 3, 2026 Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, reported its collaboration with Roche Diagnostics to validate biomarkers for patient selection in clinical trials for non-small cell lung cancer (NSCLC). Building on promising preclinical and clinical data, this collaboration intends to refine patient identification using TROP2 as a biomarker.

Genprex’s initial research demonstrated that high TROP2 H-scores and low PTEN H-scores predicted patient response in preclinical studies. These findings were further correlated with longer Progression Free Survival (PFS) in clinical studies, specifically for NSCLC patients with TROP2 H-scores above 100 and PTEN H-scores below 100. This data underscores the potential of these biomarkers to enable targeted patient selection and precision medicine. Additional data have shown that intensity of TROP2 expression may have a correlation with PFS.

"This strategic partnership with Roche Diagnostics, a recognized leader in NSCLC assay development and the recipient of an FDA Breakthrough Device Designation for their AI-driven TROP2 diagnostic, is a testament to our shared commitment to advancing precision treatments in oncology," said Ryan Confer, President and Chief Executive Officer at Genprex. "By utilizing the same validated TROP2 antibody that Roche has used in other studies, we are poised to shorten the time for patient identification and recruitment for NSCLC clinical trials, ultimately delivering more effective, personalized treatment options."

The collaboration leverages Roche Diagnostics’ expertise in assay development. Roche Diagnostics received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for the first AI-driven companion diagnostic for NSCLC that uses a TROP2 score to evaluate NSCLC specimens, and Genprex will use the same antibody against TROP2 for its validation studies. This strategic alignment ensures consistency and builds upon established diagnostic methods.

Genprex is expanding on its preclinical and clinical studies to potentially integrate TROP2 expression for patient selection in NSCLC clinical studies. Roche Diagnostics will perform the necessary assay validation using its TROP2 antibody. Genprex anticipates completing these validation studies by approximately the end of 2026, with subsequent integration into its NSCLC clinical program shortly thereafter, dependent on the results of the validation studies. This collaboration exemplifies Genprex’s commitment to delivering innovation that enables more precise diagnosis and treatment strategies in oncology, ultimately aiming to improve outcomes for NSCLC patients.

About Reqorsa Gene Therapy

REQORSA (quaratusugene ozeplasmid) consists of a plasmid containing the TUSC2 gene encapsulated in non-viral lipid-based nanoparticles in a lipoplex form (the Company’s Oncoprex Delivery System), which has a positive charge. REQORSA is injected intravenously and specifically targets cancer cells. REQORSA is designed to deliver the functioning TUSC2 gene to negatively charged cancer cells while minimizing uptake by normal tissue. Laboratory studies conducted at MD Anderson show that the uptake of TUSC2 in tumor cells in vitro after REQORSA treatment was 10 to 33 times the uptake in normal cells.

(Press release, Genprex, AUG 3, 2026, View Source [SID1234669606])

Curium Announces Definitive Agreement to Merge with Lantheus

On August 3, 2026 Curium, a leading, global radiopharmaceutical company with proven expertise in the development, manufacturing and supply of radiopharmaceuticals that improve the way cancer is diagnosed and treated, and Lantheus Holdings, Inc. ("Lantheus" or "Company") (NASDAQ: LNTH), reported that Curium US Holdings LLC ("Curium US") and Lantheus have entered into a definitive agreement under which Lantheus, a leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, will merge with a wholly-owned subsidiary of Curium US.

Under the terms of the definitive agreement, Curium US will acquire all of the outstanding shares of Lantheus for $102.50 per share in cash at closing, plus non-transferable Contingent Value Rights ("CVRs") providing for up to $12.00 per share in potential additional cash payments, subject to achievement of specified commercial milestones for Lantheus’ products through 2030. The transaction represents a total per share consideration of up to $114.50 and a total transaction value of up to approximately $8.0 billion. Together, Curium and Lantheus are positioned to create a radiopharmaceutical company spanning diagnostics and therapeutics, with the infrastructure and capabilities to serve patients in more than 70 countries. The Board of Directors of Lantheus has unanimously approved the transaction.

The cash consideration provides for near-term certain value to Lantheus shareholders at closing and the CVR structure provides meaningful potential additional upside participation in the commercial performance of Lantheus’ main product lines. The total transaction value represents a premium of 38% to Lantheus’ unaffected 60-day volume-weighted average price ("VWAP"), a premium of 29% to Lantheus’ unaffected 30-day VWAP, and a premium of 21% to Lantheus’ unaffected closing price, in each case as of May 21, 2026, the last trading day prior to the first media report of a potential sale transaction.

"Lantheus is the ideal partner to accelerate what we have been building at Curium," said Renaud Dehareng, Chief Executive Officer of Curium Group. "We have executed a strategy to build an innovative, theranostics platform by expanding our global manufacturing footprint, advancing our radioligand therapy pipeline across key regions, and positioning Curium to drive the next generation of theranostics innovation. Lantheus’ complementary business accelerates our strategy with a robust U.S. commercial infrastructure, a complementary F18-isotope based prostate diagnostics franchise and marks our entry in the U.S. market for diagnostic solutions targeting Neurology and Echocardiography. Together, we will provide meaningful theranostic options to patients from SPECT and PET diagnostics to targeted radioligand therapy across the globe. This combination unlocks an opportunity that neither company could achieve alone, as it positions us to reach significantly more patients and clinicians globally."

"We believe this transaction is the ultimate validation of what the Lantheus team has built over seven decades of innovation in radiopharmaceuticals," said Mary Anne Heino, Executive Chair and Chief Executive Officer of Lantheus. "Combining strategically with Curium brings together two pioneers with complementary strengths and a shared passion for nuclear medicine. Together, we can broaden and accelerate patient access to life-changing diagnostics and therapeutics and fully realize the differentiated outcomes and value radiopharmaceuticals can deliver. I am tremendously proud of everything our people have achieved, and I am confident this combination is the best path forward for our shareholders, our employees, and the millions of patients we serve."

Curium was established in 2017 by global investment firm CapVest Partners LLP ("CapVest") which remains its controlling shareholder and last year completed the successful recapitalization of Curium in a transaction which valued the Curium Group at approximately $7 billion. Kate Briant, Senior Partner at CapVest and Chair of Curium’s Board of Directors, said: "This transaction underlies our ongoing commitment to Curium’s growth and emphasizes our strong conviction in the potential of nuclear medicine and the future of the sector. This highly strategic combination will allow the combined company to capitalize on the significant emerging opportunities and, most importantly, will allow us to accelerate bringing life-changing solutions to healthcare professionals and benefit millions of patients (and their families) around the world."

Curium has a proven record of developing, manufacturing, and supplying diagnostic and therapeutic radiopharmaceuticals globally with a deep manufacturing expertise, and a robust theranostics pipeline. Lantheus has pioneered the radiodiagnostics landscape in the U.S. for 70 years and has demonstrated success building and growing a commercial diagnostic business, including PYLARIFY that helped establish PSMA PET as the standard of care in prostate cancer imaging, maintaining DEFINITY’s position as a category leader in cardiac ultrasound enhancing agents for 25 years, and driving Neuraceq to become the fastest-growing beta-amyloid PET agent on the market. The combined entity will span the full nuclear medicine value chain: from isotope production and manufacturing to diagnostic imaging and targeted radionuclide therapy, delivering nuclear medicine solutions to patients and healthcare systems across more than 70 countries.

The Lantheus Board of Directors, with the assistance of its financial advisors, conducted a comprehensive evaluation of its strategic options, including outreach to multiple third parties and remaining as a standalone company. After concluding this robust process, the Board unanimously determined that this transaction is in the best interests of Lantheus and its shareholders as the value maximizing path relative to the other strategic options.

Transaction Details

Under the terms of the agreement, Curium US will acquire all of the outstanding shares of Lantheus common stock for $102.50 per share in cash at closing. In addition, Lantheus shareholders will receive up to $12.00 per share in non-transferable CVRs, entitling holders to the following additional cash payments upon achievement of applicable milestones:

There can be no assurance that any payments will be made with respect to the CVRs. If all milestones are achieved, per share consideration under the CVRs would be $12.00 per share.

The transaction is expected to be financed through a combination of debt and equity and is not subject to any financial conditions or other related contingencies.

Until the transaction closes, Lantheus will continue to operate as an independent, publicly traded company. Upon completion, Lantheus will cease to be a publicly traded company.

The transaction is currently expected to close in the first half of 2027, subject to satisfaction of customary closing conditions, including receipt of Lantheus shareholder approval and required regulatory approvals.

Lantheus Second Quarter Financial Results

Lantheus is expected to announce its financial results and provide a business update for the second quarter of 2026 prior to market open on August 6, 2026. Due to the pending transaction with Curium, Lantheus will not be hosting a conference call and will be suspending its previously issued FY 2026 guidance.

Advisors

Morgan Stanley & Co. LLC acted as lead financial advisor to Lantheus, and BofA Securities, Inc. and Solomon Partners Securities LLC also acted as financial advisors to Lantheus. Covington & Burling LLP and Ropes & Gray LLP acted as legal counsel to Lantheus.

Jefferies LLC acted as lead financial advisor to Curium. J.P. Morgan Securities LLC and PJT Partners LP also acted as financial advisors to Curium. Kirkland & Ellis LLP and Arnold & Porter Kaye Scholer LLP acted as legal counsel to Curium.

(Press release, Curium Pharma, AUG 3, 2026, View Source [SID1234669605])

BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer

On August 3, 2026 BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") reported that its Supervisory Board has appointed Guido Oelkers, Ph.D., to the Management Board as Chief Executive Officer ("CEO"), who will take office by February 1, 2027, at the latest. Succeeding Prof. Ugur Sahin, M.D., Guido Oelkers will join BioNTech from the global Nasdaq Stockholm-listed biopharmaceutical company Swedish Orphan Biovitrum AB (STO: SOBI, "Sobi"), where he has served as CEO since 2017.

Guido Oelkers is a seasoned CEO and strategic leader with over 30 years of experience in the biotechnology and pharmaceutical industries. He has a strong track record in transforming and scaling global organizations, driving sustainable growth through disciplined execution, focused capital allocation, and operational excellence. Throughout his career, Guido Oelkers has successfully built, prioritized and strengthened complex and innovative product portfolios across multiple areas, including oncology and immunology, while driving strong global business operations in key markets, notably in the United States.
"Guido Oelkers is an experienced executive in the pharmaceutical industry. Throughout his impressive international career, he has consistently demonstrated sound strategic leadership in global organizations, seamlessly transforming scientific excellence into commercial success," said Helmut Jeggle, Chairman of the Supervisory Board of BioNTech. "His expertise in scaling innovation-driven organizations in a focused and capital-efficient manner, coupled with his deep knowledge in relevant markets, will position the Company well to deliver on its key objectives to become a multi-product company, and continue BioNTech’s remarkable success story."

"BioNTech stands out through its scientific foundation and particularly its strong late-stage oncology pipeline," said Guido Oelkers, Ph.D., designated Chief Executive Officer of BioNTech. "I am deeply honored to be leading BioNTech and prioritizing its evolution into a global biopharmaceutical company with multiple approved products by 2030, while continuing to advance its innovative pre-clinical and clinical portfolio in line with the Company’s strategy. I look forward to joining my colleagues on the Management Board and our teams worldwide on the journey ahead to deliver on BioNTech’s patient-centric strategy and create sustainable, long-term value."

"BioNTech is in a pivotal phase as the Company focuses on advancing its diversified pipeline into approved products and sustainable medical benefits for patients. I have come to know Guido Oelkers as a leader who combines a deep understanding of the pharmaceutical industry and strong strategic acumen with genuine respect for the culture and people of our organization," said Prof. Ugur Sahin, M.D., Chief Executive Officer and Co-Founder of BioNTech. "With Guido Oelkers taking over, I feel confident that BioNTech is in a strong position to realize its vision. To ensure a smooth and successful handover, I will be actively supporting his onboarding."

The appointment of the new CEO is the result of a comprehensive selection process led by the Supervisory Board. As previously announced, BioNTech’s Chief Medical Officer, Prof. Özlem Türeci, M.D., will transition into the management of a new, independent company, which she will lead together with her husband and co-founder, Prof. Ugur Sahin, M.D. The search for her successor is ongoing and focuses on identifying a leader with exceptional medical and scientific expertise, extensive experience in late-stage clinical development, and a proven track record of advancing innovative platforms and complex product candidates.

About Guido Oelkers

Guido Oelkers, Ph.D., is an accomplished executive who has served multiple times as CEO throughout his career at both publicly traded companies and private equity portfolio companies in Europe and the Asia-Pacific region. Most recently, he has served as CEO of Swedish Orphan Biovitrum AB ("Sobi"), where he more than quadrupled the company’s revenues over a nine-year period (financial years 2017 to 2026). During his tenure, he significantly increased Sobi’s profitability and strengthened its late-stage pipeline, positioning the company for sustained long-term success. Prior to joining Sobi, he served as CEO of the medical technology manufacturer BSN Medical Holding GmbH, as President and CEO of the Swedish medtech company Gambro AB and as CEO of the specialty pharmaceutical company Invida Holdings Pte. Ltd. Guido Oelkers held a number of executive roles in companies such as Nycomed International Management GmbH, DKSH Group, Aventis Pharma S.A. China and Hoechst AG, where he started his career. He holds a PhD in Business Management from Adelaide University, Australia, and completed his undergraduate and postgraduate studies in business management and economics in Mainz and London, respectively. Guido Oelkers is a German citizen and will be based in BioNTech’s headquarters in Mainz, Germany.

(Press release, BioNTech, AUG 3, 2026, View Source [SID1234669604])